Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01031433 · ClinicalTrials.gov registry record
Assessment of Craving in Nicotine-Dependent Patients With Schizophrenia Using Virtual Reality
A clinical trial of Nicotine Dependence, sponsored by National Institute on Drug Abuse (NIDA).
- Completed
- Registry status
- 17
- Enrollment target
- 1
- Study location
NCT01031433 is a study of Nicotine Dependence that has completed, run by National Institute on Drug Abuse (NIDA). The registered enrollment target is 17 participants, below the 186-participant average among 67 other Nicotine Dependence trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01031433, a study of Nicotine Dependence, has completed, sponsored by National Institute on Drug Abuse (NIDA).
- COMPLETED
- Registry status
- 17 participants
- Enrollment target
- 1
- Study location
Study Summary
Background: * The prevalence of cigarette smoking among individuals with schizophrenia is noticeably higher than in the general population, and smoking cessation attempts frequently are unsuccessful in this population. Little is known about the effects of cigarette/nicotine craving in individuals with schizophrenia. Researchers are interested in learning more about how craving affects people with schizophrenia and developing new ways to treat cravings and improve the effectiveness of smoking cessation therapies and treatments. * In recent years, virtual reality (VR) has been studied to determine whether it can be used to induce craving by using life-like cue settings. VR cues involving cigarette use, including images of cigarettes and scent cues of tobacco smoke, may be used to elicit craving in smokers. Researchers are interested in learning more about how individuals with schizophrenia respond to specific VR cues and settings. Objectives: * To determine the feasibility of using a contextual real-world paradigm using virtual reality involving cigarette smoking in people with schizophrenia. * To examine if virtual reality cues will elicit craving in smokers with schizophrenia. Eligibility: \- Current smokers (five or more cigarettes per day for at least 1 year) between 18 and 45 years of age who have been diagnosed with schizophrenia/schizoaffective disorder. Design: * The study will involve three sessions, with an initial screening visit, a test session, and a follow-up session. * Screening visit: Participants will be screened with a medical and psychiatric history, and will answer questions about smoking history, current smoking habits and craving patterns, and general anxiety levels. This session will also introduce participants to the operation and use of the VR equipment. Participants who are comfortable using the VR system will return within 2 days for the test session. * Test session: Participants will use the VR equipment to view neutral scenes and sc
Conditions Studied
Study Locations (1)
Maryland
- University of Maryland at Baltimore/MPRC - Catonsville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2009-07-28 |
| Est. Completion | 2012-07-18 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01031433
The ClinicalTrials.gov registry entry for NCT01031433 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 186-participant average among 67 other Nicotine Dependence trials with a reported enrollment target (91% lower). The listed sponsor is National Institute on Drug Abuse (NIDA), which has 335 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Nicotine Dependence appearing as the primary indexed condition, and to 0 interventions.
NCT01031433 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT01031433 about?
NCT01031433 is a clinical study titled "Assessment of Craving in Nicotine-Dependent Patients With Schizophrenia Using Virtual Reality". Background: * The prevalence of cigarette smoking among individuals with schizophrenia is noticeably higher than in the general population, and smoking cessation attempts frequently are unsuccessful in this population. Little is known about the effects of cigarette/nicotine craving in individuals w...
What is the current status of trial NCT01031433?
This trial is currently completed. The enrollment target is 17 participants. The study started on 2009-07-28. Estimated completion is 2012-07-18.
What conditions does trial NCT01031433 study?
This clinical trial studies the following conditions: Nicotine Dependence.
Who is sponsoring clinical trial NCT01031433?
This trial is sponsored by National Institute on Drug Abuse (NIDA), which has 335 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01031433 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Nicotine Dependence
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Pharmacokinetics and Pharmacodynamics of Nicotine With Use of Standardized Research Electronic Cigarette (SREC)
RECRUITING · NA
-
Effects of Cannabidiol on Stress and Nicotine Withdrawal
RECRUITING · Phase 1
-
Overcoming Nicotine Dependence to Enable Quitting
RECRUITING · Phase 1
-
NeuroControl of Nicotine Dependence
RECRUITING · NA
-
Beta-Adrenergic Modulation of Drug Cue Reactivity
RECRUITING · Phase 4
-
Comparative Pharmacokinetics and Pharmacodynamics of Synthetic Nicotine
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.